Aclaris Therapeutics Inc. – Filings and Transcripts

NASDAQ: ACRS
Share price (9/28/26): $5.43
Market cap (9/28/26): $799 million

Warning: Large portions of this site require JavaScript enabled in order to function properly. Please make sure JavaScript is enabled in your browser.

Please let us know at support@bamsec.com if you have any questions or concerns.

Search in Documents

Key Exhibits

External Links

Financials Filter

ended 06/30/26 Q2

ended 03/31/26 Q1

ended 12/31/25 FY 2025

ended 09/30/25 Q3

ended 06/30/25 Q2

Prospectuses and Registrations Filter

Automatic shelf registration

Registration of securities for employees

Shelf registration

Prospectus supplement

Shelf registration

Ownership Filter

Frazier Life Sciences Public Fund, L.P.

Ra Capital Management, L.P.

Kolbeck Roland Wilhelm

Humphries William D.

Molineaux Christopher P.

News Filter

Material Definitive Agreement, Financial Statements or Exhibits

Reports Second Quarter 2026 Financial Results and Provides Corporate and Clinical Update

Shareholder Vote Results

Reports First Quarter 2026 Financial Results and Provides Corporate and Clinical Update

- Positive Full Results From Phase 1a Trial of Anti-Tslp/IL-4Rα Bispecific Antibody ATI-052 Exceed Aclaris’ Target Profile, Validating Potential Best-In-Class Potency Advantage and Opportunity for Extended Dosing

Proxies Filter

Additional info about upcoming vote

Definitive proxy

Additional info about upcoming vote

Definitive proxy

Preliminary proxy

Other Filter

Scanned paper annual report submission

Scanned paper annual report submission

Notice of effectiveness

Correspondence with the SEC

Letter from the SEC